Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hutchmed China Ltd ADR (NQ: HCM ) 19.04 +0.62 (+3.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 119,971 Open 19.13 Bid (Size) 19.03 (1) Ask (Size) 19.04 (1) Prev. Close 18.42 Today's Range 18.86 - 19.44 52wk Range 11.93 - 21.92 Shares Outstanding 871,256,270 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing September 26, 2024 Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda September 24, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Performance YTD +8.74% +8.74% 1 Month +9.93% +9.93% 3 Month +9.17% +9.17% 6 Month +13.33% +13.33% 1 Year +14.08% +14.08% More News Read More International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 September 17, 2024 From Virtual Investor Conferences Via GlobeNewswire HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer September 08, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China August 30, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia August 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Hutchmed scores U.S. success with cancer drug, but profits still dip August 15, 2024 Via Benzinga HUTCHMED Reports 2024 Interim Results and Provides Business Updates July 31, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Why HUTCHMED Stock Is Moving Higher Friday July 05, 2024 Via Benzinga HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status July 03, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED to Announce 2024 Half-Year Financial Results June 26, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 June 24, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda June 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology June 16, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China June 06, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine June 02, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting May 23, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees May 17, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress May 16, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China May 13, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui May 13, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday May 09, 2024 Via Benzinga HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee May 08, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda April 26, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion April 06, 2024 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.